|
 |
|
|
| Breaking News on Outsourcing Pharma |
||
|
||
| Daily
Monday 17 December 2007 |
 Forward to a colleague |
|
|
Access Full Stories  Patheon reveals plans to tackle Puerto Rico problemsPatheon has finally revealed its plans to tackle the ongoing problems it has been facing with its Puerto Rican operations, which are draining the firm of profitability... Read ClinTec to take on India UK contract research organisation (CRO) ClinTec has outlined new expansion plans into India to try its luck in this country's burgeoning clinical contract research arena... Read Japan says Tamiflu/psychiatric link unclear Any link between the antiviral Tamiflu and neuropsychiatric problems is inconclusive, according to the Japanese Government... Read West Pharma unit to suffer in post-Exubera fallout The repercussions of Pfizer's dramatic Exubera exit are finally filtering through to West Pharmaceutical Services, with the company preparing to restructure its affected Tech Group contract manufacturing unit... Read China's API manufacturers facing further crackdowns The first steps in tightening the safety controls on the pharmaceutical ingredients imported to the US from China have been taken following months of negotiations between the regulatory bodies of the two countries... Read |
|
||||||||||||
All News Headlines for: December | November | October |
||||||||||||||
 Sponsored LinkDPT - The Industry Source for Semi-solids and Liquids. DPT is a contract development and manufacturing organization (CDMO) specializing in semi-solid and liquid dosage forms providing solutions from concept to commercialization. Click here to learn more about our services... Click Here | ||||||||||||||
|
||||||||||||||
|
Related Industry News Semen fibrils ferry HIV into cells Tiny protein fibres in semen have been found to enhance the ability of HIV to infect cells by up to 100,000 fold and could provide drug developers with a potent new target to tackle the virus... Read Biogen Idec shares nosedive after withdrawing 'for sale' sign Like countless pets after every Christmas, it seems that nobody wanted Biogen Idec after all; the firm has announced it will remain independent after it 'did not receive any definitive offers to purchase the company'... Read Roche targets Ventana's board to force takeover The latest twist in Roche's long-running bid to acquire diagnostics expert Ventana has seen the pharma giant announce it intends to elect directors to Ventana's board at its next AGM (annual general meeting)... Read Eisai continues biologics push with $3.9bn MGI Pharma buy Japanese drugmaker Eisai has agreed to buy US biopharma firm MGI Pharma for $3.9bn (€2.7bn) in a bid to expand its US presence and strengthen its oncology pipeline... Read
|
||||||||||||||
|
|
|
|||
| Forward to a colleague |
|||||
|
To continue to receive this newsletter in your inbox, please add newsletter@OutSourcing-Pharma.com to your address book |
|
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||
